Durvalumab with or without Olaparib for endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial collects safety information on the standard use of Durvalumab (with or without Olaparib) in people with endometrial cancer in Korea. It helps doctors confirm the real-world effects of these approved treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have endometrial cancer and your doctor plans to use Durvalumab (with or without Olaparib) as approved in Korea.
- You are not currently in another research trial that tests a new treatment while on this drug.
- You (or your legal representative) sign a consent form agreeing to take part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well two drugs, durvalumab and olaparib, work together after initial chemotherapy for advanced or recurrent endometrial cancer. It may help patients who have not had many treatment options before.
This trial tests two immunotherapy drugs, durvalumab and tremelimumab, in people with colorectal or endometrial cancer that has spread or come back. The goal is to understand why some tumors persist or don't respond to treatment.
This trial tests a chemotherapy combination (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab, followed by maintenance pembrolizumab either alone or with a PARP inhibitor called nesuparib. It is for women with advanced or recurrent endometrial cancer that is MMR-proficient (a type where the cells have a normal ability to fix DNA).
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
This study tests whether olaparib and durvalumab given around the time of diagnosis can help people with advanced ovarian cancer. It also strongly focuses on collecting tumor and blood samples to better understand who may benefit.
This trial tests adding durvalumab (an immune therapy) to a radiation treatment plan for people with non-small cell lung cancer (NSCLC) who can’t safely have chemotherapy at the same time or surgery first. It aims to improve cancer control after radiation by helping the immune system recognize and fight the tumor.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.